Blarcamesine hydrochloride is under clinical development by Anavex Life Sciences and currently in Phase I for Fragile X Syndrome. According to GlobalData, Phase I drugs for Fragile X Syndrome does not have sufficient historical data to build an indication benchmark PTSR for Phase I. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the Blarcamesine hydrochloride LoA Report. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Blarcamesine hydrochloride overview
Blarcamesine hydrochloride (ANAVEX-273, AE-37) is under development for the treatment of Angelman syndrome, fragile X syndrome, infantile spasms, Alzheimer’s disease, gait abnormality, Parkinson's disease dementia, tuberous sclerosis, Rett syndrome, systolic hypertension, insomnia and undisclosed rare disease. The drug candidate is administered orally or intravenously. The drug candidate is a tetrahydrofuran disease modification agent. It is a prodrug of ANAVEX 19-144. Anavex-273 targets sigma-1, muscarinic M1-4 receptors, sodium alpha subunit and NMDA receptor. The drug candidate is based on SIGMACEPTOR-N program. It was also under development for stroke, amyotrophic lateral sclerosis, anxiety, amnesia, depression and multiple sclerosis.
Anavex Life Sciences overview
Anavex Life Sciences (Anavex) is a clinical-stage biopharmaceutical company that focuses on developing differentiated therapeutics for the treatment of neurodegenerative and other central nervous systems (CNS) diseases, pain, and various types of cancer. The company’s target indications include Alzheimer’s disease, Parkinson’s disease, Rett syndrome, epilepsy, neuropathic pain, depression, prostate cancer, pancreatic cancer infantile spasms, fragile X syndrome, Angelman syndrome, visceral pain, multiple sclerosis, depression, stroke, frontotemporal dementia, acute and neuropathic Pain and malignant melanoma. Its pipeline comprises one drug candidate and several compounds in diverse stages of pre-clinical study. Anavex’s lead compound ANAVEX 2-73 is being developed for the treatment of Alzheimer’s disease, Parkinson’s disease and potentially other CNS diseases, including rare diseases. Anavex is headquartered in New York, the US.
For a complete picture of Blarcamesine hydrochloride’s drug-specific PTSR and LoA scores, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
